118 related articles for article (PubMed ID: 4086246)
1. A phase I trial of ametantrone acetate (NSC-287513).
Gams RA; Ostroy F; Bender JF; Grillo-López AJ
Invest New Drugs; 1985; 3(4):383-8. PubMed ID: 4086246
[TBL] [Abstract][Full Text] [Related]
2. Phase I investigation of ametantrone.
Loesch DM; Von Hoff DD; Kuhn J; Coltman CA; Tio F; Chaudhuri TK; Bender JF; Grillo-Lopez AJ
Cancer Treat Rep; 1983 Nov; 67(11):987-91. PubMed ID: 6640557
[TBL] [Abstract][Full Text] [Related]
3. Preclinical toxicity of the new antineoplastic agent, ametantrone acetate, in mice and dogs.
Watkins JR; Kim SN; Jayasekara U; Anderson JA; Fitzgerald JE; de la Iglesia FA
J Appl Toxicol; 1986 Feb; 6(1):31-6. PubMed ID: 3958426
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ametantrone acetate (NSC-287513).
Kuhn JG; Balmer CE; Ludden TM; Loesch DM; Von Hoff DD; Bender JF; Grillo-Lopez AJ
Cancer Chemother Pharmacol; 1987; 19(2):133-7. PubMed ID: 3568271
[TBL] [Abstract][Full Text] [Related]
6. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of intravenous menogaril administered intermittently.
Dodion P; Sessa C; Joss R; Crespeigne N; Willems Y; Kitt M; Abrams J; Finet C; Brewer JE; Adams WJ
J Clin Oncol; 1986 May; 4(5):767-74. PubMed ID: 2939203
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion.
Leyvraz S; Ohnuma T; Lassus M; Holland JF
J Clin Oncol; 1985 Oct; 3(10):1385-92. PubMed ID: 3900302
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of mitoxantrone on a daily X 5 schedule.
Goldsmith MA; Ohnuma T; Jaffrey IH; Greenspan EM; Holland JF
Am J Clin Oncol; 1984 Oct; 7(5):567-70. PubMed ID: 6507380
[TBL] [Abstract][Full Text] [Related]
13. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
[TBL] [Abstract][Full Text] [Related]
14. Clinical and clinical pharmacologic studies of mitoxantrone.
Stewart JA; McCormack JJ; Krakoff IH
Cancer Treat Rep; 1982 Jun; 66(6):1327-31. PubMed ID: 7083236
[TBL] [Abstract][Full Text] [Related]
15. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial with ametantrone (NSC-287513).
Piccart M; Rozencweig M; Abele R; Cumps E; Dodion P; Dupont D; Kisner D; Kenis Y
Eur J Cancer Clin Oncol; 1981 Jul; 17(7):775-9. PubMed ID: 7199472
[No Abstract] [Full Text] [Related]
18. Mitoxantrone in malignant lymphoma.
Gams RA; Steinberg J; Posner L
Semin Oncol; 1984 Sep; 11(3 Suppl 1):47-9. PubMed ID: 6484580
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
